Chicago, May 25 – UBS AG, London Branch priced $1.42 million of trigger autocallable contingent yield notes due Nov. 2, 2023 linked to the common stock of Crispr Therapeutics AG, according to a 424B2 filing with the Securities and Exchange Commission.
Each quarter, the notes will pay a coupon at the rate of 16% per year if the stock closes at or above its coupon barrier, 65% of its initial level, on any related observation date.
The notes will be automatically called at par plus the coupon if the stock closes at or above 85% of its initial level on any quarterly call observation date.
If the notes are not called and the final share price is greater than or equal to the downside threshold level, 55% of the initial share price, the payout at maturity will be par. Otherwise, investors will lose 1% for every 1% that the final share price declines from its initial share price.
UBS Securities LLC and UBS Investment Bank are the agents.
| Issuer: | UBS AG, London Branch
|
| Issue: | Trigger autocallable contingent yield notes
|
| Underlying stock: | Crispr Therapeutics AG
|
| Amount: | $1,420,000
|
| Maturity: | Nov. 2, 2023
|
| Coupon: | 16% per year, paid quarterly, if the stock closes at or above its coupon barrier on any related observation date
|
| Price: | Par
|
| Payout at maturity: | Par unless the stock finishes below downside threshold level, in which case 1% loss for each 1% decline from initial level
|
| Call: | Automatically at par plus coupon if the stock closes at or above 85% of the initial level on any quarterly call observation date
|
| Initial level: | $91.33
|
| Coupon barrier level: | $59.36; 65% of initial level
|
| Downside threshold: | $50.23; 55% of initial level
|
| Call level: | $77.63; 85% of initial level
|
| Pricing date: | Oct. 29, 2021
|
| Settlement date: | Nov. 3, 2021
|
| Agents: | UBS Securities LLC and UBS Investment Bank
|
| Fees: | 2.5%
|
| Cusip: | 90279DNS1
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
